FR15C0060I1 - - Google Patents

Info

Publication number
FR15C0060I1
FR15C0060I1 FR15C0060C FR15C0060I1 FR 15C0060 I1 FR15C0060 I1 FR 15C0060I1 FR 15C0060 C FR15C0060 C FR 15C0060C FR 15C0060 I1 FR15C0060 I1 FR 15C0060I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR15C0060I1 publication Critical patent/FR15C0060I1/fr
Application granted granted Critical
Publication of FR15C0060I2 publication Critical patent/FR15C0060I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR15C0060C 1996-12-20 2015-09-07 Compositions pharmaceutiques comprenant un analogue d'un nucleotide destinees a la lyophilisation Active FR15C0060I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation
PCT/SE1997/002068 WO1998028009A1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying

Publications (2)

Publication Number Publication Date
FR15C0060I1 true FR15C0060I1 (h) 2015-10-23
FR15C0060I2 FR15C0060I2 (fr) 2016-04-22

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0060C Active FR15C0060I2 (fr) 1996-12-20 2015-09-07 Compositions pharmaceutiques comprenant un analogue d'un nucleotide destinees a la lyophilisation

Country Status (35)

Country Link
US (1) US6114313A (h)
EP (1) EP1007094B1 (h)
JP (1) JP4488538B2 (h)
KR (1) KR100552880B1 (h)
CN (1) CN1121875C (h)
AR (1) AR010377A1 (h)
AT (1) ATE221787T1 (h)
AU (1) AU758857B2 (h)
BR (1) BR9713974B1 (h)
CA (1) CA2275153C (h)
CZ (1) CZ300635B6 (h)
DE (1) DE69714616T2 (h)
DK (1) DK1007094T3 (h)
EE (1) EE03857B1 (h)
ES (1) ES2182133T3 (h)
FR (1) FR15C0060I2 (h)
HU (1) HU226616B1 (h)
ID (1) ID21635A (h)
IL (1) IL130449A0 (h)
IS (1) IS1897B (h)
MY (1) MY121982A (h)
NO (1) NO327142B1 (h)
NZ (1) NZ336027A (h)
PL (1) PL190493B1 (h)
PT (1) PT1007094E (h)
RU (1) RU2205012C2 (h)
SA (1) SA97180719B1 (h)
SE (1) SE9604795D0 (h)
SI (1) SI1007094T1 (h)
SK (1) SK283137B6 (h)
TR (1) TR199901412T2 (h)
TW (1) TW522015B (h)
UA (1) UA66779C2 (h)
WO (1) WO1998028009A1 (h)
ZA (1) ZA9711055B (h)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112013020377B1 (pt) 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
WO2014143107A1 (en) 2013-03-09 2014-09-18 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
PE20171246A1 (es) * 2015-01-14 2017-08-24 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
KR102768341B1 (ko) 2017-06-23 2025-02-18 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (h) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Atp凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
KR0131678B1 (ko) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
KR100315612B1 (ko) * 1993-02-10 2002-06-20 추후제출 N-알킬-2-치환아데노신트리포스페이트동족체

Also Published As

Publication number Publication date
BR9713974B1 (pt) 2010-02-23
IS5064A (is) 1999-06-03
NZ336027A (en) 2001-03-30
WO1998028009A1 (en) 1998-07-02
EE03857B1 (et) 2002-10-15
HUP0000572A3 (en) 2002-10-28
BR9713974A (pt) 2000-04-11
HU226616B1 (en) 2009-04-28
AU5351598A (en) 1998-07-17
FR15C0060I2 (fr) 2016-04-22
JP2001507022A (ja) 2001-05-29
NO993067L (no) 1999-08-09
RU2205012C2 (ru) 2003-05-27
KR100552880B1 (ko) 2006-02-20
MY121982A (en) 2006-03-31
TW522015B (en) 2003-03-01
DK1007094T3 (da) 2002-10-28
EP1007094A1 (en) 2000-06-14
NO993067D0 (no) 1999-06-21
PT1007094E (pt) 2002-12-31
JP4488538B2 (ja) 2010-06-23
DE69714616D1 (de) 2002-09-12
ATE221787T1 (de) 2002-08-15
CN1240362A (zh) 2000-01-05
SI1007094T1 (en) 2003-02-28
HUP0000572A2 (hu) 2001-05-28
ZA9711055B (en) 1998-07-08
AR010377A1 (es) 2000-06-07
CA2275153A1 (en) 1998-07-02
IL130449A0 (en) 2000-06-01
KR20000069598A (ko) 2000-11-25
SE9604795D0 (sv) 1996-12-20
NO327142B1 (no) 2009-05-04
CA2275153C (en) 2008-03-25
UA66779C2 (uk) 2004-06-15
TR199901412T2 (xx) 1999-08-23
CN1121875C (zh) 2003-09-24
US6114313A (en) 2000-09-05
AU758857B2 (en) 2003-04-03
CZ300635B6 (cs) 2009-07-08
PL190493B1 (pl) 2005-12-30
SK283137B6 (sk) 2003-03-04
EP1007094B1 (en) 2002-08-07
HK1026366A1 (en) 2000-12-15
ID21635A (id) 1999-07-08
IS1897B (is) 2003-10-20
SK76499A3 (en) 1999-11-08
SA97180719B1 (ar) 2006-05-13
CZ220199A3 (cs) 1999-11-17
DE69714616T2 (de) 2003-04-03
ES2182133T3 (es) 2003-03-01
EE9900260A (et) 2000-02-15
PL334006A1 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
AR026660A2 (h)
BRPI9713914B8 (h)
FR15C0060I1 (h)
IN181540B (h)
IN191438B (h)
IN183686B (h)
IN186439B (h)
IN189571B (h)
IN192561B (h)
IN185667B (h)
BR9603859A (h)
ITMI960195A0 (h)
ITMI960498V0 (h)
BR7600721U (h)
IN188405B (h)
IN186517B (h)
BR7601346U (h)
ITAN960010A0 (h)
IN186352B (h)
CN3039060S (h)
CN3041374S (h)
CN3042193S (h)
CN3040543S (h)
CN3040367S (h)
CN3047076S (h)